Theprimarygoalofthisproposalistodevelopandapplyaninvitromodelofthe neuromuscularjunction(NMJ)usingmotorneuronsandmusclebothderivedfromhumaninduced pluripotentstemcells(iPSCs).Theresearchwillcombinestate-of-the-artstemcellbiology,gene targeting,electrophysiologyandgenomictechniques.Themainfocusoftheapplicationwillbein amyotrophiclateralsclerosis(ALS),commonlyknownasLouGehrig?sdisease,whichisadevastating diseaseofthemotornervoussystemwithanonsetoftenintheprimeoflifeandanaveragesurvivalof onlytwotothreeyears.ALSaffectsabout20,000peopleintheUSatanytime.About10%ofcases areduetodominantfamilialmutationsand90%areapparentlysporadic.DegenerationoftheNMJis theearliestpathologicalfeatureofALSinbothhumansandmousemodels.Involuntarymuscle contractions,knownasfasciculations,arethefirstclinicaldiseasesymptomandreflectabnormalmotor neuronelectricaldischarges,whichoriginateinthedistalaxonandNMJ.TheNMJnovelmodelbrings tobeartheadvantagesofhumanstemcellapproaches,namely,toovercomelimitsofmousemodels includingartifactsthatresultfromheterologousover-expressionofhumanproteinsinamouse backgroundandinabilitytocapturecomplexitiesofdiversehumangeneticbackgroundsinmice. Furthermore,mousemodelsarelimitedtothefamilialformsofthedisease,whileiPSC-basedmodels havethepotentialtoaddresssporadicdisease,thevastmajorityofALScases.Theapplicationsofthe modeldescribedintheprotocolincludeidentifyingmorphologicalandgenomicphenotypesoftheALS NMJ,determininghowthemotorneuronandmuscleeachcontributetoabnormalmotorneuron physiologyandreciprocallyhowabnormalmotorneuronexcitabilityaffectstheNMJ.Thesequestions willbeaddressedacrossarangeoffamilialandsporadicALSvariants.Whilestillclearlyreductionist, themodelgoesbeyondisolatediPSC-derivedmotorneuronstoaddthedisease-relevantanatomical contextoftheNMJandthusgiveadditionalstructuralmeaningtoneuronalcomponentsliketheinitial axonsegment,axonanddistalmotorterminalsandmechanisticprocessesimplicatedinALSsuch axonaltransport.ThehumanNMJmodeldevelopedintheproposedprojectwillbeusefultoidentify specificALSsubgroupsthatsharecommondiseasemechanismsandtofindtargetsandevaluate candidatetherapeuticsappropriateforthoseindividualdiseasesubgroups.Themodelwillalsobe broadlyapplicabletoothermotorneurondiseases,suchasspinalmuscularatrophy,aswellasmotor neuropathiesandmyopathies.

Public Health Relevance

Theproposedresearchwilldevelopamodelusinghumaninducedpluripotentstemcellsofthe neuromuscularjunction,thesiteofinitialclinicalandpathologicalfeaturesofamyotrophiclateral sclerosis,commonlyknownasLouGehrig?sdisease.Theproposedresearchwillcombineinnovative stemcellbiology,electrophysiologyandgenomicsandleadtomoleculartargetsandtreatment strategiesforthisdevastatingcondition.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
NIH Director’s New Innovator Awards (DP2)
Project #
1DP2NS106664-01
Application #
9350551
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Gubitz, Amelie
Project Start
2017-09-25
Project End
2022-06-30
Budget Start
2017-09-25
Budget End
2022-06-30
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114